JP2021514187A5 - - Google Patents
Info
- Publication number
- JP2021514187A5 JP2021514187A5 JP2020543545A JP2020543545A JP2021514187A5 JP 2021514187 A5 JP2021514187 A5 JP 2021514187A5 JP 2020543545 A JP2020543545 A JP 2020543545A JP 2020543545 A JP2020543545 A JP 2020543545A JP 2021514187 A5 JP2021514187 A5 JP 2021514187A5
- Authority
- JP
- Japan
- Prior art keywords
- tme
- expression vector
- promoter
- responsive expression
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631095P | 2018-02-15 | 2018-02-15 | |
| US62/631,095 | 2018-02-15 | ||
| US201862784501P | 2018-12-23 | 2018-12-23 | |
| US62/784,501 | 2018-12-23 | ||
| PCT/IL2019/050182 WO2019159173A1 (en) | 2018-02-15 | 2019-02-14 | Tumor environment-specific expression of chimeric antigen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514187A JP2021514187A (ja) | 2021-06-10 |
| JP2021514187A5 true JP2021514187A5 (https=) | 2022-02-17 |
Family
ID=65904511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543545A Pending JP2021514187A (ja) | 2018-02-15 | 2019-02-14 | キメラ抗原受容体の腫瘍環境特異的発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210030799A1 (https=) |
| EP (2) | EP3619313B9 (https=) |
| JP (1) | JP2021514187A (https=) |
| CN (1) | CN111971394B (https=) |
| AU (1) | AU2019221324A1 (https=) |
| CA (1) | CA3093628A1 (https=) |
| IL (1) | IL276636A (https=) |
| WO (1) | WO2019159173A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021053678A1 (en) * | 2019-09-22 | 2021-03-25 | The National Institute for Biotechnology in the Negev Ltd. | Tumor environment specific expression of effector genes |
| US20230364137A1 (en) * | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| CN118105504A (zh) * | 2022-11-29 | 2024-05-31 | 深圳先进技术研究院 | 一种具有肿瘤微环境响应的乳酸杆菌载体及应用 |
| CN118685362A (zh) * | 2024-05-15 | 2024-09-24 | 西安电子科技大学 | 一种癌环境响应型的过继单核或巨噬细胞免疫治疗生物制品及其在抗肿瘤中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| AU2017342176A1 (en) * | 2016-10-10 | 2019-05-02 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
-
2019
- 2019-02-14 CN CN201980025929.0A patent/CN111971394B/zh not_active Expired - Fee Related
- 2019-02-14 CA CA3093628A patent/CA3093628A1/en active Pending
- 2019-02-14 AU AU2019221324A patent/AU2019221324A1/en not_active Abandoned
- 2019-02-14 US US16/968,861 patent/US20210030799A1/en not_active Abandoned
- 2019-02-14 EP EP19713223.6A patent/EP3619313B9/en active Active
- 2019-02-14 WO PCT/IL2019/050182 patent/WO2019159173A1/en not_active Ceased
- 2019-02-14 EP EP23177824.2A patent/EP4279501A3/en not_active Withdrawn
- 2019-02-14 JP JP2020543545A patent/JP2021514187A/ja active Pending
-
2020
- 2020-08-11 IL IL276636A patent/IL276636A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514187A5 (https=) | ||
| EP2925349B1 (en) | Tumor specific t-cell receptors | |
| JP7653962B2 (ja) | 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法 | |
| JP5292550B2 (ja) | Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子 | |
| JP2023503163A5 (https=) | ||
| Bontkes et al. | Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells | |
| Cappello et al. | LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| JP2018523485A5 (https=) | ||
| JP2018522567A (ja) | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 | |
| JP2022521183A5 (https=) | ||
| CN105802909B (zh) | 具有her2特异性tcr的t细胞制备物及其用途 | |
| WO2019020089A1 (zh) | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 | |
| JP2021516049A5 (https=) | ||
| Ahmetlić et al. | Regulatory T cells in an endogenous mouse lymphoma recognize specific antigen peptides and contribute to immune escape | |
| Gu et al. | Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| Stewart et al. | Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+ Gr-1+ myeloid cells | |
| WO2018052142A1 (ja) | 遺伝子改変細胞及びその作製方法 | |
| Inoue et al. | Identification of SPARC as a candidate target antigen for immunotherapy of various cancers | |
| CN109306340B (zh) | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 | |
| CN109970846A (zh) | 一种肿瘤相关抗原XAGE-1b九肽及其应用 | |
| Yang et al. | Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma | |
| CN106279392A (zh) | 肿瘤相关抗原XAGE‑1b短肽及其应用 | |
| JP2024526090A5 (https=) |